Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

Phase 3 Completed 72 enrolled Institut de Recerca Biomèdica de Lleida Fundació La Marató de TV3 · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate whether the administration of iron to patients with heart failure and preserved ejection fraction results in an improvement of symptoms and functional class, in addition to evaluating whether oral iron is equivalent to intravenous iron to achieve this improvement.

Timeline

Start: 2017-08-23
Primary completion: 2024-09-15
Completion: 2024-12-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ferric carboxymaltose	Other / unclassified	500 mg	Intravenous
Comparator	Ferric carboxymaltose	Other / unclassified	1000 mg	Intravenous
Comparator	Ferroglycine Sulfate	Small molecule	100 mg	Oral
Comparator	Sucrosomial Iron	Unknown	30 mg	Oral

Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

Summary

Timeline

Drugs

Indications